We have previously shown that HepaRG-progenitors resistant to sorafenib or cisplatin express increased mRNA levels of PDK4 and that the combination of chemotherapy with the PDK4 inhibitor (DCA) is effective in killing immature HCC cells [11]. This evidence concerns the gene PDK4 and hepatocellular carcinoma.